<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220009</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-01239</org_study_id>
    <secondary_id>NCI-2017-01239</secondary_id>
    <secondary_id>A091603</secondary_id>
    <secondary_id>A091603</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <nct_id>NCT03220009</nct_id>
  </id_info>
  <brief_title>Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma</brief_title>
  <official_title>A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well nivolumab or expectant observation following&#xD;
      ipilimumab, nivolumab, and surgery work in treating patients with high-risk mucosal melanoma&#xD;
      that is restricted to the site of origin without evidence of spread, has spread to a local&#xD;
      and regional area of the body, or has come back. Monoclonal antibodies, such as nivolumab and&#xD;
      ipilimumab, may interfere with the ability of tumor cells to grow and spread. Sometimes the&#xD;
      mucosal melanoma may not need more treatment until it progresses. In this case, observation&#xD;
      may be sufficient. It is not known if nivolumab or expectant observation following&#xD;
      ipilimumab, nivolumab, and surgery may be better in treating patients with mucosal melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Recurrence free survival (RFS) in patients with mucosal melanoma (MM) treated with&#xD;
      neoadjuvant ipilimumab plus nivolumab and surgery followed by adjuvant nivolumab and&#xD;
      expectant observation.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Pathologic complete response with neoadjuvant ipilimumab plus nivolumab. II. Distant&#xD;
      recurrence-free survival (DRFS) with adjuvant nivolumab and expectant observation.&#xD;
&#xD;
      III. Overall survival (OS) with adjuvant nivolumab and expectant observation. IV.&#xD;
      Safety/toxicity as measured by maximum grade adverse event in (a) the neoadjuvant setting,&#xD;
      (b) the adjuvant nivolumab cohort after randomization, and (c) the observation cohort after&#xD;
      randomization.&#xD;
&#xD;
      V. Rate of delayed primary surgery.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Demonstrate that baseline tumors harboring a higher neoepitope burden have superior median&#xD;
      RFS than those who have a lower neoepitope burden in the arm receiving adjuvant nivolumab.&#xD;
&#xD;
      II. Demonstrate that tumors with higher CD8+ infiltration at the tumor invasive margin at&#xD;
      surgical resection have superior median RFS than those with lower CD8+ infiltration.&#xD;
&#xD;
      III. Demonstrate that tumors harboring a &quot;T cell inflamed&quot; ribonucleic acid (RNA) expression&#xD;
      signature at surgical resection following neoadjuvant nivolumab plus ipilimumab have a&#xD;
      superior distant RFS than those harboring a &quot;non-T cell inflamed&quot; signature, both in the&#xD;
      overall group and within those who receive adjuvant nivolumab.&#xD;
&#xD;
      IV. Identify recurrent genetic alterations at baseline that are associated with higher&#xD;
      CD8+/PD1+ infiltration at baseline and following 1 dose of neoadjuvant nivolumab plus&#xD;
      ipilimumab.&#xD;
&#xD;
      V. Tumor response rate will be estimated based on patients whose imaging are captured and&#xD;
      submitted during the neo-adjuvant portion of the study (imaging is not required).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PART I: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over&#xD;
      30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients&#xD;
      undergo surgery per standard of care. Within 84 days of last surgical resection, patients may&#xD;
      also undergo adjuvant radiation therapy (RT), if clinically appropriate.&#xD;
&#xD;
      PART II: Within 84 days of last surgical resection, patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo active surveillance for 1 year.&#xD;
&#xD;
      ARM II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses.&#xD;
      Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to&#xD;
      11 doses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 90 days for 2 years,&#xD;
      every 180 days for 3 years or until disease progression, whichever is first, and every 6&#xD;
      months thereafter until a maximum of 5 years following registration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was never approved by CTEP neither was it ever activated&#xD;
  </why_stopped>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>From randomization to either adjuvant nivolumab or observation until evidence of disease recurrence, assessed up to 5 years</time_frame>
    <description>RFS of patients receiving adjuvant nivolumab will be compared to patients undergoing observation. Kaplan- Meier curves will be constructed and median RFS times will be calculated for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence-free survival (DRFS)</measure>
    <time_frame>From randomization to either adjuvant nivolumab or observation until a distant recurrence is observed, assessed up to 5 years</time_frame>
    <description>Will be evaluated using the Kaplan- Meier method. Median times to DRFS will be calculated for each arm and a cox proportional hazards model will be constructed to determine if there is a DRFS benefit for patients in the adjuvant Nivolumab arm (compared to observation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Maximum grade adverse events will be summarized in each of the following settings: during the neo-adjuvant phase of the trial (i.e. from registration until a patient is randomized to adjuvant nivolumab or observation), the adjuvant nivolumab arm after randomization, he observation arm after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to either adjuvant nivolumab or observation until death due to any cause; assessed up to 5 years</time_frame>
    <description>Will be evaluated using the Kaplan- Meier method. Median OS times will be calculated for each arm and a cox proportional hazards model will be constructed to determine if there is a DRFS benefit for patients in the adjuvant Nivolumab arm (compared to observation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delayed surgery</measure>
    <time_frame>Up to 6 weeks after registration</time_frame>
    <description>Reasons for delay will be summarized and the rate of delay will be calculated along with a 95% confidence interval using the properties of the binomial distribution.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CD8+ infiltration</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>CD8+ infiltration levels will be compared to RFS times using a cox proportional hazards model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neoepitope burden</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Neoepitope burden will be compared to RFS using a cox proportional hazards model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathologic complete response prior to surgery, for patients with imaging available</measure>
    <time_frame>Up to time of surgery, assessed up to 5 years</time_frame>
    <description>The rate of pathologic complete response will be estimated using and a 95% confidence interval will be calculated using properties of the binomial distribution.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrent genetic alterations</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Patients will be categorized by driver mutation, including BRAF, RAS family (NRAS/KRAS/HRAS), KIT, and/or NF1 alterations. The degree of CD8+ and/or PD-L1 infiltration will be compared across various categories of driver mutation using descriptive statistics. Pending further advances in genomic understanding of these tumors, alternate categories may be constructed.</description>
  </other_outcome>
  <other_outcome>
    <measure>T cell inflammation</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Patients will be categorized has having a &quot;T dell inflamed&quot; RNA expression signature versus a &quot;non-T cell inflamed&quot; signature. These groups will be compared to each other in terms of RFS times using a cox proportional hazards model. An additional model will be constructed with randomized arm included to determine if there is an interaction between signature and arm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cervical Carcinoma</condition>
  <condition>Esophageal Carcinoma</condition>
  <condition>Mucosal Melanoma</condition>
  <condition>Mucosal Melanoma of the Head and Neck</condition>
  <condition>Oral Cavity Mucosal Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage II Vulvar Cancer AJCC v7</condition>
  <condition>Stage III Vulvar Cancer AJCC v7</condition>
  <condition>Stage IIIA Vulvar Cancer AJCC v7</condition>
  <condition>Stage IIIB Vulvar Cancer AJCC v7</condition>
  <condition>Stage IIIC Vulvar Cancer AJCC v7</condition>
  <condition>Stage IV Oral Cavity Cancer AJCC v6 and v7</condition>
  <condition>Stage IV Vulvar Cancer AJCC v7</condition>
  <condition>Stage IVA Oral Cavity Cancer AJCC v6 and v7</condition>
  <condition>Stage IVB Oral Cavity Cancer AJCC v6 and v7</condition>
  <condition>Stage IVC Oral Cavity Cancer AJCC v6 and v7</condition>
  <condition>Vaginal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.&#xD;
PART II: Patients undergo active surveillance for 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.&#xD;
PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
    <other_name>Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA4</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Observation</intervention_name>
    <description>Undergo active surveillance</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <other_name>Active Surveillance</other_name>
    <other_name>deferred therapy</other_name>
    <other_name>expectant management</other_name>
    <other_name>observation</other_name>
    <other_name>Watchful Waiting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo RT</description>
    <arm_group_label>Arm I (nivolumab, ipilimumab, surgery, active surveillance)</arm_group_label>
    <arm_group_label>Arm II (nivolumab, ipilimumab, surgery, nivolumab)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>irradiation</other_name>
    <other_name>RADIATION</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  STEP 1 ELIGIBILITY CRITERIA&#xD;
&#xD;
          -  Documentation of disease:&#xD;
&#xD;
               -  Histologic documentation: histologically proven mucosal melanoma by local&#xD;
                  pathology&#xD;
&#xD;
               -  Tumor tissue: tumor tissue from the primary site of disease must be available for&#xD;
                  PD-L1 testing (stratification factor)&#xD;
&#xD;
          -  Disease status&#xD;
&#xD;
               -  Tumors must have NOT been completely resected, or must be locoregionally&#xD;
                  recurrent if previously resected; tumor must be deemed potentially resectable by&#xD;
                  local surgeon&#xD;
&#xD;
               -  MM arising from the head/neck, genitourinary, or gastrointestinal tract&#xD;
&#xD;
               -  Disease meets any 1 of 4 characteristics:&#xD;
&#xD;
                    -  Regional lymph node (LN) involvement; OR&#xD;
&#xD;
                    -  Multifocal/satellite primary disease; OR&#xD;
&#xD;
                    -  Single localized, primary disease meeting one of the following site-specific&#xD;
                       requirements:&#xD;
&#xD;
                         -  Head/neck - any primary lesion if sinonasal; pT4a or above for nasal or&#xD;
                            oral cavity&#xD;
&#xD;
                         -  Anorectal - any primary lesion&#xD;
&#xD;
                         -  Conjunctiva - any primary lesion T2 or T3 stage by American Joint&#xD;
                            Committee on Cancer (AJCC)&#xD;
&#xD;
                         -  Vaginal/cervical - any primary&#xD;
&#xD;
                         -  Vulvar (hair bearing surface, labia majora) - AJCC cutaneous stage IIB&#xD;
                            or higher&#xD;
&#xD;
                         -  Esophageal - any primary&#xD;
&#xD;
                    -  Locoregionally recurrent following prior resection&#xD;
&#xD;
               -  No evidence of metastatic disease at the time of registration&#xD;
&#xD;
          -  No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy)&#xD;
             or radiation therapy for MM, unless locoregionally recurrent; if recurrent, no prior&#xD;
             medical or radiation therapy is allowed for the latest recurrence&#xD;
&#xD;
          -  No history of the following:&#xD;
&#xD;
               -  Active known or suspected autoimmune disease&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV) with CD4+ count &lt; 300 or detectable viral&#xD;
                  load; patients with HIV, undetectable viral load, and CD4+ count &gt;= 300 are&#xD;
                  eligible&#xD;
&#xD;
               -  Known active hepatitis B or C&#xD;
&#xD;
                    -  Hepatitis B can be defined as:&#xD;
&#xD;
                         -  Hepatitis B virus surface antigen (HBsAg) &gt; 6 months&#xD;
&#xD;
                         -  Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml&#xD;
                            (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml)&#xD;
                            are often seen in hepatitis B virus e antigen (HBeAg)-negative chronic&#xD;
                            hepatitis B&#xD;
&#xD;
                         -  Persistent or intermittent elevation in alanine aminotransferase&#xD;
                            (ALT)/aspartate aminotransferase (AST) levels&#xD;
&#xD;
                         -  Liver biopsy showing chronic hepatitis with moderate or severe&#xD;
                            necroinï¬‚ammation&#xD;
&#xD;
                    -  Hepatitis C can be defined as:&#xD;
&#xD;
                         -  Hepatitis C antibody (AB) positive&#xD;
&#xD;
                         -  Presence of hepatitis C virus (HCV) RNA&#xD;
&#xD;
               -  Known active pulmonary disease with hypoxia defined as oxygen saturation &lt; 85% on&#xD;
                  room air&#xD;
&#xD;
          -  Not pregnant and not nursing&#xD;
&#xD;
               -  For women of childbearing potential only, a negative pregnancy test done =&lt; 14&#xD;
                  days prior to registration is required&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance &gt;= 30 mL/min by Modified Diet in Renal Disease (MDRD) equation or&#xD;
             Cockcroft-Gault&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Except in case of Gilbert disease&#xD;
&#xD;
          -  AST/ALT =&lt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) within normal limits (WNL)&#xD;
&#xD;
               -  Supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH&#xD;
                  if free T4 is normal and patient is clinically euthyroid, patient is eligible&#xD;
&#xD;
          -  Concomitant medications&#xD;
&#xD;
               -  No systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone&#xD;
                  equivalents) or other immunosuppressive medications within 7 days of registration&#xD;
                  (inhaled steroids for patients with underlying chronic pulmonary disease is&#xD;
                  acceptable as long as they meet other eligibility as listed above)&#xD;
&#xD;
               -  No other planned concurrent investigational agents or other tumor directed&#xD;
                  therapy (chemotherapy, radiation) while on study&#xD;
&#xD;
          -  STEP 2 ELIGIBILITY CRITERIA&#xD;
&#xD;
          -  Surgical resection of all gross disease&#xD;
&#xD;
               -  This assessment will be made by the local investigator based on review of the&#xD;
                  operative report, pathology results, and/or radiology reports; microscopically&#xD;
                  positive margins (e.g. R1 resection) are permitted&#xD;
&#xD;
          -  Completion of PD-L1 testing&#xD;
&#xD;
               -  Patients will be stratified as PD-L1 &gt;= 5% versus (vs) &lt; 5% OR inevaluable;&#xD;
                  baseline tumor will be utilized; if this returns inevaluable, efforts should be&#xD;
                  made to utilize the resected specimen&#xD;
&#xD;
          -  Randomization within 112 days of completion of surgical&#xD;
&#xD;
               -  The primary region must be included on cross-sectional imaging (e.g. sinus/neck&#xD;
                  if arising from sinonasal primary; pelvis if genitourinary); radiographic changes&#xD;
                  considered nonspecific or possibly due to surgery or radiation are not considered&#xD;
                  evidence of disease&#xD;
&#xD;
          -  No significant immune-related adverse event due to the nivolumab plus ipilimumab dose&#xD;
             received in the neoadjuvant setting, as follows:&#xD;
&#xD;
               -  Any grade myocarditis, including an asymptomatic troponin elevation felt to be&#xD;
                  related to nivolumab plus ipilimumab&#xD;
&#xD;
               -  Any grade neurologic complication (e.g. meningitis, encephalitis, neuropathy);&#xD;
                  study chair should be contacted if there is any question whether an adverse event&#xD;
                  (AE) was neurologic in nature&#xD;
&#xD;
               -  Grade 2 or higher pneumonitis&#xD;
&#xD;
               -  Grade 2 colitis&#xD;
&#xD;
               -  Grade 2 or higher anemia (due to drug; unrelated anemia is not exclusionary)&#xD;
&#xD;
               -  Thyroid/adrenal AEs regardless of grade that have stabilized or are clinically&#xD;
                  asymptomatic are eligible&#xD;
&#xD;
               -  Fatigue, regardless of grade, is not a contraindication to randomization&#xD;
&#xD;
               -  Grade 4 AST or ALT elevation&#xD;
&#xD;
               -  Asymptomatic elevated amylase and lipase, regardless of grade, are not&#xD;
                  contraindications to randomization&#xD;
&#xD;
               -  Grade 4 rash; grade 3 rash is not a contraindication to randomization; any&#xD;
                  oropharyngeal lesions or bullous skin lesions that are suggestive of toxic&#xD;
                  epidermal necrolysis or Stevens-Johnson syndrome are contraindications to&#xD;
                  randomization regardless of the grade of rash&#xD;
&#xD;
                    -  If not specified above, other Common Terminology Criteria for Adverse Events&#xD;
                       (CTCAE) grade 3 or higher AEs deemed possibly related to the nivolumab plus&#xD;
                       ipilimumab are exclusions to randomization; AEs that were attributable to&#xD;
                       surgery or adjuvant RT would not be contraindications to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Shoushtari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance for Clinical Trials in Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance for Clinical Trials in Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

